Johnson & Johnson: Keep Calm And Hold On

Johnson & Johnson (JNJ) reported Q3 2026 earnings, showing growth in consumer health and pharmaceuticals, but facing challenges in medical devices.

The company maintained its full-year guidance.

Want to stay up to date with the world events at sea or at home?